Last reviewed · How we verify
Graceway Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Aldara (imiquimod) cream, 5% | Aldara (imiquimod) cream, 5% | marketed | TLR7 agonist | TLR7 (Toll-like receptor 7) | Oncology, Dermatology, Immunology |
Therapeutic area mix
- Oncology, Dermatology, Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Apotex Inc. · 1 shared drug class
- Elion Therapeutics, Inc. · 1 shared drug class
- MEDA Pharma GmbH & Co. KG · 1 shared drug class
- Medical University of Graz · 1 shared drug class
- Medical University of Vienna · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Graceway Pharmaceuticals, LLC:
- Graceway Pharmaceuticals, LLC pipeline updates — RSS
- Graceway Pharmaceuticals, LLC pipeline updates — Atom
- Graceway Pharmaceuticals, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Graceway Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/graceway-pharmaceuticals-llc. Accessed 2026-06-10.